Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Q34664479)

3 August 2017

title

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (English)

1 reference

ORCID Public Data File 2021

3 August 2017

1 reference

author name string

ESMO/European Sarcoma Network Working Group

series ordinal

1

1 reference

3 August 2017

publication date

1 September 2014

1 reference

3 August 2017

1 reference

3 August 2017

volume

25 Suppl 3

1 reference

3 August 2017

page(s)

iii102-12

1 reference

Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Cediranib for metastatic alveolar soft part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Response to sunitinib malate in advanced alveolar soft part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Sunitinib malate in solitary fibrous tumor (SFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Retroperitoneal sarcomas: combined modality treatment approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Endometrial stromal sarcoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Hormonal therapy for aggressive angiomyxoma: a case report and proposed management algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Therapy of desmoid tumors and fibromatosis using vinorelbine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Desmoid tumors respond to chemotherapy: defying the dogma in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Activity of Sorafenib against desmoid tumor/deep fibromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Stud

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

Evaluating the risks of electric uterine morcellation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU254

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU254

1 reference

3 August 2017

1 reference